Ratings by RBC Capital (Gregory Renza)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/1/2026 | Pacira Pharmaceuticals | PCRX | Maintain | Sector Perform (N/A) |
|
Details | ||
| 12/3/2025 | ADC Therapeutics | ADCT | Maintain | Outperform (N/A) |
|
Details | ||
| 11/19/2025 | Agios Pharma | AGIO | Downgrade | Sector Perform (Outperform) |
45.49 (27.68) |
-39.15% | Details | |
| 8/21/2025 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 8/8/2025 | Verastem | VSTM | Maintain | Outperform (N/A) |
|
Details | ||
| 7/30/2025 | Fulcrum Therapeutics | FULC | Maintain | Sector Perform (N/A) |
|
Details | ||
| 7/17/2025 | Bicycle Therapeutics | BCYC | Maintain | Outperform (N/A) |
|
Details | ||
| 7/16/2025 | CG Oncology | CGON | Maintain | Outperform (N/A) |
|
Details | ||
| 7/8/2025 | Jasper Therapeutics | JSPR | Downgrade | Sector Perform (Outperform) |
3.04 (0.53) |
-82.57% | Details | |
| 6/23/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 6/20/2025 | CorMedix | CRMD | Maintain | Outperform (N/A) |
|
Details | ||
| 6/20/2025 | ADC Therapeutics | ADCT | Maintain | Outperform (N/A) |
|
Details | ||
| 6/3/2025 | Perspective Therapeutics Inc | CATX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/23/2025 | Cidara Therapeutics | CDTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/19/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2025 | Exelixis | EXEL | Maintain | Outperform (N/A) |
|
Details | ||
| 5/13/2025 | Jasper Therapeutics | JSPR | Maintain | Outperform (N/A) |
|
Details | ||
| 5/9/2025 | Verastem | VSTM | Maintain | Outperform (N/A) |
|
Details | ||
| 5/9/2025 | Cidara Therapeutics | CDTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/7/2025 | Viridian Therapeutic | VRDN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/7/2025 | Jazz Pharmaceuticals | JAZZ | Maintain | Outperform (N/A) |
|
Details | ||
| 4/16/2025 | Spruce Biosciences, Inc. | SPRB | Maintain | Sector Perform (N/A) |
|
Details | ||
| 4/8/2025 | Pacira Pharmaceuticals | PCRX | Maintain | Sector Perform (N/A) |
|
Details | ||
| 4/3/2025 | Jazz Pharmaceuticals | JAZZ | Maintain | Outperform (N/A) |
|
Details | ||
| 4/3/2025 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/28/2025 | ADC Therapeutics | ADCT | Maintain | Outperform (N/A) |
|
Details | ||
| 3/27/2025 | Perspective Therapeutics Inc | CATX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/13/2025 | Exelixis | EXEL | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2025 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2025 | Viridian Therapeutic | VRDN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2025 | Pacira Pharmaceuticals | PCRX | Maintain | Sector Perform (N/A) |
|
Details | ||
| 2/26/2025 | Jazz Pharmaceuticals | JAZZ | Maintain | Outperform (N/A) |
|
Details | ||
| 2/5/2025 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/29/2025 | Nurix | NRIX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/9/2025 | Jasper Therapeutics | JSPR | Maintain | Outperform (N/A) |
|
Details | ||
| 1/7/2025 | Verastem | VSTM | Maintain | Outperform (N/A) |
|
Details | ||
| 1/7/2025 | Pacira Pharmaceuticals | PCRX | Maintain | Sector Perform (N/A) |
|
Details | ||
| 1/7/2025 | Nuvation Bio Inc | NUVB | Maintain | Outperform (N/A) |
|
Details | ||
| 1/7/2025 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 12/19/2024 | CorMedix | CRMD | Maintain | Outperform (N/A) |
|
Details | ||
| 12/19/2024 | MannKind | MNKD | Upgrade | Outperform (Sector Perform) |
5.93 (7.00) |
18.04% | Details | |
| 12/17/2024 | Viridian Therapeutic | VRDN | Maintain | Outperform (N/A) |
|
Details | ||
| 12/17/2024 | Ideaya Biosciences | IDYA | Maintain | Outperform (N/A) |
|
Details | ||
| 12/13/2024 | Cidara Therapeutics | CDTX | New Coverage | Outperform (N/A) |
21.64 (105.99) |
389.79% | Details | |
| 12/11/2024 | Spruce Biosciences, Inc. | SPRB | Maintain | Sector Perform (N/A) |
|
Details | ||
| 12/10/2024 | Agios Pharma | AGIO | Maintain | Outperform (N/A) |
|
Details | ||
| 11/25/2024 | Perspective Therapeutics Inc | CATX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/15/2024 | Inovio Pharmaceuticals | INO | Maintain | Sector Perform (N/A) |
|
Details | ||
| 9/26/2024 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 9/24/2024 | Ideaya Biosciences | IDYA | Maintain | Outperform (N/A) |
|
Details | ||
| 9/23/2024 | CG Oncology | CGON | New Coverage | Outperform (N/A) |
39.00 (54.42) |
39.54% | Details | |
| 9/13/2024 | Viridian Therapeutic | VRDN | Maintain | Outperform (N/A) |
|
Details | ||
| 9/12/2024 | Fulcrum Therapeutics | FULC | Downgrade | Sector Perform (Outperform) |
8.85 (3.22) |
-63.62% | Details | |
| 9/6/2024 | Bicycle Therapeutics | BCYC | New Coverage | Outperform (N/A) |
20.59 (8.18) |
-60.27% | Details | |
| 9/3/2024 | Fulcrum Therapeutics | FULC | Maintain | Outperform (N/A) |
|
Details | ||
| 8/16/2024 | Perspective Therapeutics Inc | CATX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/14/2024 | Jasper Therapeutics | JSPR | Maintain | Outperform (N/A) |
|
Details | ||
| 8/9/2024 | Inovio Pharmaceuticals | INO | Maintain | Sector Perform (N/A) |
|
Details | ||
| 8/7/2024 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/7/2024 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 7/12/2024 | Nurix | NRIX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/11/2024 | Ideaya Biosciences | IDYA | Maintain | Outperform (N/A) |
|
Details | ||
| 7/9/2024 | Morphic Therapeutic | MORF | Downgrade | Sector Perform (Outperform) |
31.84 (56.99) |
78.99% | Details | |
| 6/27/2024 | Nurix | NRIX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/14/2024 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 6/14/2024 | Perspective Therapeutics Inc | CATX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/14/2024 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 6/11/2024 | Viridian Therapeutic | VRDN | Maintain | Outperform (N/A) |
|
Details | ||
| 6/11/2024 | Nurix | NRIX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/28/2024 | Verastem | VSTM | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2024 | Perspective Therapeutics Inc | CATX | New Coverage | Outperform (N/A) |
1.75 (3.56) |
103.43% | Details | |
| 5/3/2024 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/26/2024 | Morphic Therapeutic | MORF | Maintain | Outperform (N/A) |
|
Details | ||
| 4/11/2024 | Nurix | NRIX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/11/2024 | Alpine Immune Sciences | ALPN | Downgrade | Sector Perform (Outperform) |
38.94 (64.97) |
66.85% | Details | |
| 3/27/2024 | Jasper Therapeutics | JSPR | New Coverage | Outperform (N/A) |
27.89 (0.53) |
-98.1% | Details | |
| 3/20/2024 | Fusion Pharmaceuticals | FUSN | Downgrade | Sector Perform (Outperform) |
10.64 (21.55) |
102.54% | Details | |
| 3/13/2024 | Spruce Biosciences, Inc. | SPRB | Downgrade | Sector Perform (Outperform) |
4.96 (49.05) |
888.91% | Details | |
| 3/13/2024 | Fulcrum Therapeutics | FULC | New Coverage | Outperform (N/A) |
10.91 (3.22) |
-70.49% | Details | |
| 3/13/2024 | CorMedix | CRMD | Maintain | Outperform (N/A) |
|
Details | ||
| 3/12/2024 | Alpine Immune Sciences | ALPN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/12/2024 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 3/4/2024 | Fusion Pharmaceuticals | FUSN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2024 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 2/26/2024 | Spruce Biosciences, Inc. | SPRB | Maintain | Outperform (N/A) |
|
Details | ||
| 2/20/2024 | Ideaya Biosciences | IDYA | Maintain | Outperform (N/A) |
|
Details | ||
| 2/7/2024 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/10/2024 | Ideaya Biosciences | IDYA | Maintain | Outperform (N/A) |
|
Details | ||
| 1/9/2024 | Alpine Immune Sciences | ALPN | Maintain | Outperform (N/A) |
|
Details | ||
| 12/20/2023 | Fusion Pharmaceuticals | FUSN | New Coverage | Outperform (N/A) |
6.03 (21.55) |
257.38% | Details | |
| 12/12/2023 | Amgen | AMGN | Upgrade | Outperform (Sector Perform) |
272.14 (338.22) |
24.28% | Details | |
| 11/15/2023 | CorMedix | CRMD | Maintain | Outperform (N/A) |
|
Details | ||
| 11/10/2023 | Aptose Biosciences | APTO | Maintain | Outperform (N/A) |
|
Details | ||
| 11/8/2023 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 11/6/2023 | Morphic Therapeutic | MORF | Maintain | Outperform (N/A) |
|
Details | ||
| 11/3/2023 | Alpine Immune Sciences | ALPN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/3/2023 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 11/2/2023 | Nurix | NRIX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/31/2023 | Viridian Therapeutic | VRDN | Maintain | Outperform (N/A) |
|
Details | ||
| 10/24/2023 | Ideaya Biosciences | IDYA | Maintain | Outperform (N/A) |
|
Details | ||
| 10/13/2023 | Nurix | NRIX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/5/2023 | Alpine Immune Sciences | ALPN | New Coverage | Outperform (N/A) |
11.58 (64.97) |
461.05% | Details | |
| 8/11/2023 | Aptose Biosciences | APTO | Maintain | Outperform (N/A) |
|
Details | ||
| 8/10/2023 | Ideaya Biosciences | IDYA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/10/2023 | CorMedix | CRMD | New Coverage | Outperform (N/A) |
4.35 (8.23) |
89.2% | Details | |
| 8/9/2023 | Verastem | VSTM | Maintain | Outperform (N/A) |
|
Details | ||
| 7/3/2023 | Verastem | VSTM | Maintain | Outperform (N/A) |
|
Details | ||
| 6/26/2023 | Avalo Therapeutics Inc. | AVTX | Downgrade | Sector Perform (Outperform) |
4.42 (13.74) |
210.86% | Details | |
| 5/30/2023 | Viridian Therapeutic | VRDN | New Coverage | Outperform (N/A) |
23.73 (16.35) |
-31.1% | Details | |
| 5/10/2023 | Avalo Therapeutics Inc. | AVTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/8/2023 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 4/26/2023 | Morphic Therapeutic | MORF | Maintain | Outperform (N/A) |
|
Details | ||
| 4/24/2023 | Ideaya Biosciences | IDYA | Maintain | Outperform (N/A) |
|
Details | ||
| 4/18/2023 | Prometheus Biosciences Inc | RXDX | Downgrade | Sector Perform (Outperform) |
114.01 (199.92) |
75.35% | Details | |
| 2/28/2023 | Ideaya Biosciences | IDYA | New Coverage | Outperform (N/A) |
17.35 (28.40) |
63.69% | Details | |
| 2/10/2023 | Nurix | NRIX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/4/2023 | Prometheus Biosciences Inc | RXDX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/7/2022 | Prometheus Biosciences Inc | RXDX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/7/2022 | Prometheus Biosciences Inc | RXDX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/18/2022 | Provention Bio Inc. | PRVB | Maintain | Sector Perform (N/A) |
|
Details | ||
| 11/8/2022 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 11/4/2022 | Verastem | VSTM | Maintain | Outperform (N/A) |
|
Details | ||
| 11/4/2022 | Provention Bio Inc. | PRVB | Maintain | Sector Perform (N/A) |
|
Details | ||
| 11/3/2022 | Morphic Therapeutic | MORF | Maintain | Outperform (N/A) |
|
Details | ||
| 11/3/2022 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 11/2/2022 | Aptose Biosciences | APTO | Maintain | Outperform (N/A) |
|
Details | ||
| 10/4/2022 | Prometheus Biosciences Inc | RXDX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/30/2022 | BELLUS Health Inc. | BLU | Maintain | Outperform (N/A) |
|
Details | ||
| 8/12/2022 | Prometheus Biosciences Inc | RXDX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/9/2022 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 8/9/2022 | Global Blood Therapeutics | GBT | Downgrade | Sector Perform (Outperform) |
63.84 (68.49) |
7.28% | Details | |
| 8/5/2022 | Avalo Therapeutics Inc. | AVTX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/4/2022 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 8/4/2022 | Morphic Therapeutic | MORF | Maintain | Outperform (N/A) |
|
Details | ||
| 7/13/2022 | BELLUS Health Inc. | BLU | Maintain | Outperform (N/A) |
|
Details | ||
| 6/21/2022 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 6/15/2022 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 5/13/2022 | Prometheus Biosciences Inc | RXDX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/10/2022 | Aptose Biosciences | APTO | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2022 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2022 | Avalo Therapeutics Inc. | AVTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/5/2022 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 4/18/2022 | Nurix | NRIX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/14/2022 | Verastem | VSTM | New Coverage | Outperform (N/A) |
1.47 (3.62) |
146.26% | Details | |
| 3/16/2022 | Aprea | APRE | Maintain | Sector Perform (N/A) |
|
Details | ||
| 3/15/2022 | Spruce Biosciences, Inc. | SPRB | Maintain | Outperform (N/A) |
|
Details | ||
| 3/3/2022 | Avalo Therapeutics Inc. | AVTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/2/2022 | Inovio Pharmaceuticals | INO | Maintain | Sector Perform (N/A) |
|
Details | ||
| 2/25/2022 | Morphic Therapeutic | MORF | Maintain | Outperform (N/A) |
|
Details | ||
| 12/21/2021 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 12/17/2021 | BELLUS Health Inc. | BLU | Maintain | Outperform (N/A) |
|
Details | ||
| 12/13/2021 | Prometheus Biosciences Inc | RXDX | New Coverage | Outperform (N/A) |
33.38 (199.92) |
498.92% | Details | |
| 11/12/2021 | Gamida Cell Ltd. | GMDA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/5/2021 | Global Blood Therapeutics | GBT | Maintain | Outperform (N/A) |
|
Details | ||
| 11/1/2021 | Inovio Pharmaceuticals | INO | Maintain | Sector Perform (N/A) |
|
Details | ||
| 10/18/2021 | BELLUS Health Inc. | BLU | Maintain | Outperform (N/A) |
|
Details | ||
| 9/24/2021 | Avalo Therapeutics Inc. | AVTX | New Coverage | Outperform (N/A) |
2.46 (13.74) |
458.54% | Details | |
| 9/2/2021 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 8/13/2021 | Aprea | APRE | Maintain | Sector Perform (N/A) |
|
Details | ||
| 5/11/2021 | Inovio Pharmaceuticals | INO | Maintain | Sector Perform (N/A) |
|
Details | ||
| 5/7/2021 | Provention Bio Inc. | PRVB | Maintain | Sector Perform (N/A) |
|
Details | ||
| 5/7/2021 | Aprea | APRE | Maintain | Sector Perform (N/A) |
|
Details | ||
| 5/6/2021 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2021 | Global Blood Therapeutics | GBT | Maintain | Outperform (N/A) |
|
Details | ||
| 4/9/2021 | Provention Bio Inc. | PRVB | Downgrade | Sector Perform (Outperform) |
9.74 (24.98) |
156.47% | Details | |
| 3/17/2021 | Aprea | APRE | Maintain | Sector Perform (Sector Perform) |
|
Details | ||
| 3/10/2021 | Gamida Cell Ltd. | GMDA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/9/2021 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 2/24/2021 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 2/2/2021 | Morphic Therapeutic | MORF | Maintain | Outperform (N/A) |
|
Details | ||
| 1/29/2021 | BELLUS Health Inc. | BLU | New Coverage | Outperform (N/A) |
3.13 (14.74) |
370.93% | Details | |
| 12/28/2020 | Aprea | APRE | Downgrade | Sector Perform (Outperform) |
25.09 (0.76) |
-96.97% | Details | |
| 12/15/2020 | Gamida Cell Ltd. | GMDA | Maintain | Outperform (N/A) |
|
Details | ||
| 12/3/2020 | Global Blood Therapeutics | GBT | New Coverage | Outperform (N/A) |
44.78 (63.84) |
42.56% | Details | |
| 11/16/2020 | Inovio Pharmaceuticals | INO | Maintain | Sector Perform (N/A) |
|
Details | ||
| 11/10/2020 | Inovio Pharmaceuticals | INO | Maintain | Sector Perform (N/A) |
|
Details | ||
| 11/3/2020 | Spruce Biosciences, Inc. | SPRB | New Coverage | Outperform (N/A) |
20.30 (49.05) |
141.63% | Details | |
| 10/26/2020 | Morphic Therapeutic | MORF | New Coverage | Outperform (N/A) |
28.66 (31.84) |
11.1% | Details | |
| 8/12/2020 | Gamida Cell Ltd. | GMDA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/12/2020 | Aprea | APRE | Maintain | Outperform (N/A) |
|
Details | ||
| 8/11/2020 | Inovio Pharmaceuticals | INO | Maintain | Sector Perform (N/A) |
|
Details | ||
| 8/5/2020 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 8/5/2020 | Aptose Biosciences | APTO | Maintain | Outperform (N/A) |
|
Details | ||
| 6/4/2020 | Provention Bio Inc. | PRVB | New Coverage | Outperform (N/A) |
14.48 (24.98) |
72.51% | Details | |
| 6/2/2020 | Inovio Pharmaceuticals | INO | Maintain | Sector Perform (N/A) |
|
Details | ||
| 6/2/2020 | Iterum Therapeutics | ITRM | Downgrade | Sector Perform (Outperform) |
4.21 (0.03) |
-99.29% | Details | |
| 5/15/2020 | Iterum Therapeutics | ITRM | Maintain | Outperform (N/A) |
|
Details | ||
| 5/8/2020 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 5/7/2020 | Inovio Pharmaceuticals | INO | Maintain | Sector Perform (N/A) |
|
Details | ||
| 5/6/2020 | Aptose Biosciences | APTO | Maintain | Outperform (N/A) |
|
Details | ||
| 4/23/2020 | Portola Pharmaceuticals | PTLA | New Coverage | Outperform (N/A) |
6.76 (18.03) |
166.72% | Details | |
| 3/13/2020 | Iterum Therapeutics | ITRM | Maintain | Outperform (N/A) |
|
Details | ||
| 3/13/2020 | Inovio Pharmaceuticals | INO | Downgrade | Sector Perform (Outperform) |
8.37 (1.14) |
-86.38% | Details | |
| 3/11/2020 | Aptose Biosciences | APTO | Maintain | Outperform (N/A) |
|
Details | ||
| 2/10/2020 | Inovio Pharmaceuticals | INO | Maintain | Outperform (N/A) |
|
Details | ||
| 1/30/2020 | Xencor, Inc. | XNCR | New Coverage | Outperform (N/A) |
33.79 (11.42) |
-66.2% | Details | |
| 1/23/2020 | Inovio Pharmaceuticals | INO | Maintain | Outperform (N/A) |
|
Details | ||
| 12/11/2019 | Iterum Therapeutics | ITRM | Maintain | Outperform (N/A) |
|
Details | ||
| 12/10/2019 | ArQule | ARQL | Downgrade | Sector Perform (Outperform) |
9.67 (20.00) |
106.83% | Details | |
| 11/14/2019 | Gamida Cell Ltd. | GMDA | Maintain | Outperform (N/A) |
|
Details | ||
| 10/28/2019 | Aprea | APRE | New Coverage | Outperform (N/A) |
25.59 (25.09) |
-1.95% | Details | |
| 10/9/2019 | ArQule | ARQL | Maintain | Outperform (N/A) |
|
Details | ||
| 8/15/2019 | Iterum Therapeutics | ITRM | Maintain | Outperform (N/A) |
|
Details | ||
| 6/19/2019 | ArQule | ARQL | Maintain | Outperform (N/A) |
|
Details | ||
| 5/15/2019 | Iterum Therapeutics | ITRM | Maintain | Outperform (N/A) |
|
Details | ||
| 5/10/2019 | Inovio Pharmaceuticals | INO | Maintain | Outperform (N/A) |
|
Details | ||
| 5/8/2019 | Gamida Cell Ltd. | GMDA | Maintain | Outperform (N/A) |
|
Details | ||
| 5/2/2019 | ArQule | ARQL | Maintain | Outperform (N/A) |
|
Details | ||
| 4/11/2019 | ArQule | ARQL | New Coverage | Outperform (N/A) |
5.43 (20.00) |
268.32% | Details | |
| 3/27/2019 | Iterum Therapeutics | ITRM | Maintain | Outperform (N/A) |
|
Details | ||
| 3/13/2019 | Inovio Pharmaceuticals | INO | Maintain | Outperform (N/A) |
|
Details | ||
| 3/1/2019 | Aptose Biosciences | APTO | New Coverage | Outperform (N/A) |
1.76 (1.71) |
-2.84% | Details | |
| 11/20/2018 | Gamida Cell Ltd. | GMDA | New Coverage | Outperform (N/A) |
9.60 (0.03) |
-99.69% | Details | |
| 11/15/2018 | Iterum Therapeutics | ITRM | Maintain | Outperform (N/A) |
|
Details |
